34 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28017532	140	Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors.	Astrazeneca
24735644	19	Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.	University of Lille
19596577	26	Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.	Dipartimento Di Chimica
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
15658862	30	Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.	University Institute of Pathology
10669576	65	Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.	Novartis Institute For Biomedical Research
10882358	62	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.	F. Hoffmann-La Roche
9554884	72	Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.	Novartis Pharmaceuticals
7783143	66	Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.	Berlex Laboratories
8421284	7	Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency.	Monsanto
	29	Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11	TBA
	22	Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11	TBA
	65	Solid phase synthesis of phosphinic acid endothelin converting enzyme inhibitors	TBA
	18	Highly potent and selective inhibitors of endothelin converting enzyme	TBA
	11	Thiol and hydroxamic acid containing inhibitors of endothelin converting enzyme	TBA
19899765	69	Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.	Cea
	8	Optimization of retro-thiorphan for inhibition of endothelin converting enzyme	TBA
16821800	96	Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.	Pfizer
16085415	34	Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.	Bayer Healthcare
12372501	21	Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1.	Novartis Institute For Biomedical Research
12113828	63	N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.	University of Paris
12067547	16	Synthesis of triazole-Tethered pyrrolidine libraries: novel ECE inhibitors.	F. Hoffmann-La Roche
11384231	26	2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.	F. Hoffmann-La Roche
32150407	27	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.	Qpex Biopharma
11212114	16	Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.	Novartis Institute For Biomedical Research
27563406	128	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.	Roche Pharma Research and Early Development
10987444	16	Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.	Novartis Institute For Biomedical Research
10476884	1	Synthesis of a phostone glycomimetic of the endothelin converting enzyme inhibitor phosphoramidon.	Université
9873497	17	Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1).	Warner-Lambert
9484512	130	Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.	Shionogi
30655952	89	Discovery of TD-0212, an Orally Active Dual Pharmacology AT	Theravance Biopharma Us